BioNTech (NASDAQ:BNTX) Stock Price Down 0.9% – What’s Next?

BioNTech SE (NASDAQ:BNTX)’s stock price fell 0.9% during mid-day trading on Friday . The company traded as low as $117.79 and last traded at $119.58. 226,396 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 814,359 shares. The stock had previously closed at $120.72.

Analysts Set New Price Targets

BNTX has been the subject of several research reports. UBS Group boosted their price target on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. Bank of America increased their target price on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Deutsche Bank Aktiengesellschaft raised their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $138.67.

BioNTech Trading Down 1.9 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company’s 50 day simple moving average is $113.69 and its two-hundred day simple moving average is $98.50. The company has a market cap of $28.38 billion, a PE ratio of -56.94 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that BioNTech SE will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its position in shares of BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after buying an additional 238 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares in the last quarter. Planning Capital Management Corp increased its position in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its position in shares of BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after purchasing an additional 1,562 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.